Your browser doesn't support javascript.
loading
Imatinib pharmacokinetics and creatine kinase levels in chronic myeloid leukemia patients: implications for therapeutic response and monitoring.
Omran, Mervat M; Ibrahim, Amel B; Abdelfattah, Raafat; Shouman, Samia A; Hamza, Marwa S.
Afiliación
  • Omran MM; Pharmacology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, 11796, Egypt. Mervat.omran@nci.cu.edu.eg.
  • Ibrahim AB; Department of Pharmacology, Faculty of Medicine, Zawia University, Zawia, Libya.
  • Abdelfattah R; Medical Oncology Department, National Cancer Institute, Cairo University, Cairo, Egypt.
  • Shouman SA; Pharmacology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, 11796, Egypt.
  • Hamza MS; Clinical Pharmacy Practice Department, Faculty of Pharmacy, The British University in Egypt, El-Sherouk City, Cairo, Egypt.
Eur J Clin Pharmacol ; 80(7): 1061-1068, 2024 Jul.
Article en En | MEDLINE | ID: mdl-38536418
ABSTRACT

BACKGROUND:

Imatinib treatment for certain cancers can lead to elevated creatine kinase (CK) levels, potentially indicating muscle injury, and ongoing research aims to understand the correlation between imatinib levels and creatine kinase to assess its impact on treatment response.

METHODS:

This single-center observational study involved 76 chronic myeloid leukemia (CML) patients receiving imatinib treatment, focusing on evaluating drug and metabolite levels using liquid chromatography-mass spectrometry (LC-MS-MS) instrumentation. Serum CK and creatine kinase-MB (CK-MB) levels were assessed using Colorimetric kits.

RESULTS:

CK and CK-MB levels were measured, CK showed a median value of 211.5 IU/l and CK-MB showed a median value of 4.4 IU/l. Comparing low and high CK groups, significant differences were found in peak and trough plasma concentrations of imatinib and its metabolites. Correlations between CK levels and pharmacokinetic parameters were explored, with notable associations identified. Binary logistic regression revealed predictors influencing the therapeutic response to imatinib and categorized expected CK levels into high or low, with peak levels of imatinib emerging as a significant predictor for CK level categorization.

CONCLUSION:

The study highlights the link between imatinib's pharmacokinetics and elevated CK levels, indicating a possible correlation between specific metabolites and improved treatment response. Individualized monitoring of CK levels and imatinib pharmacokinetics could enhance care for CML patients.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Mielógena Crónica BCR-ABL Positiva / Monitoreo de Drogas / Creatina Quinasa / Mesilato de Imatinib / Antineoplásicos Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Clin Pharmacol Año: 2024 Tipo del documento: Article País de afiliación: Egipto Pais de publicación: Alemania
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Mielógena Crónica BCR-ABL Positiva / Monitoreo de Drogas / Creatina Quinasa / Mesilato de Imatinib / Antineoplásicos Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Clin Pharmacol Año: 2024 Tipo del documento: Article País de afiliación: Egipto Pais de publicación: Alemania